Ascaltis' oral small molecule GLP-1, ASC30, demonstrated a 1.7% reduction in placebo-adjusted HbA1c at 12 weeks from a US phase II study in participants with diabetes -. Company announcement - FT.com.
🇺🇸 USA · Map
Ascaltis' oral small molecule GLP-1, ASC30, demonstrated a 1.7% reduction in placebo-adjusted HbA1c at 12 weeks from a US phase II study in participants with diabetes -. Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in